comparemela.com

Latest Breaking News On - Meeting of the gastrointestinal drugs advisory committee - Page 1 : comparemela.com

FDA Committee Votes Against Risk-Benefit Profile of OCA 25 mg for NASH

The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.